Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma-Reference-Cited by-同舟云学术

Different sensitivity of CD19-positive bone marrow and lymph node lymphoblasts may cause resistance to blinatumomab in relapsed B-cell acute lymphoblastic leukemia/lymphoma

Published:2020-01-03 Issue:5 Volume:61 Page:1230-1233
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Ivanov Vadim¹,Farnault Laure¹,Mercier Cedric¹,Colavolpe Cecile²,Venton Geoffroy¹³,Colle Julien¹,Lepidi Hubert⁴,Arnoux Isabelle⁵,Nicolino-Brunet Corinne⁶,Berda-Haddad Yael⁶,Fanciullino Raphaelle⁷⁸,Ivanov Gleb⁹,Costello Regis¹³

Affiliation:

1. Department of Hematology, La Conception, University Hospital of Marseille, Marseille, France;

2. Department of Nuclear Medicine, La Timone & North University Hospital, Aix-Marseille University, Marseille, France;

3. INSERM, Marseille, France;

4. Department of Pathology, CHU La Conception, AP-HM, Marseille, France;

5. Department of Hematology, CHU La Timone, AP-HM, Marseille, France;

6. Department of Hematology and Vascular Biology, CHU La Conception, AP-HM, Marseille, France;

7. Pharmacy Unit, La Conception, University Hospital of Marseille, APHM, Marseille, France;

8. SMARTc Unit, Pharmacokinetics Laboratory, Marseille, France;

9. Surrey and Sussex NHS Trust, Redhill, UK

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1706737

Reference15 articles.

1. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

2. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia

3. Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab

4. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

5. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma